Psychiatr. pro Praxi, 2006; 1: 8-11

CURRENT TRENDS IN THE BIOLOGICAL TREATMENT OF ALZHEIMER DISEASE

doc. MUDr. Roman Jirák CSc
Psychiatrická klinika 1. LF UK a VFN Praha

We do not knot complex etiology of Alzheimer disease so far. That is why we are not able to treat such a sever dementia causally. Procedures that affect known pathogenetic chains are used. Evidence based management is only a treatment with acetylcholineesterase inhibitors and memantin. Some other procedures are reported, but their effect is not positively confirmed as with procedures mentioned above.

Keywords: Key words: Alzheimer disease, dementia, acetylcholineesterase inhibitors, cognitive function, memantin, nerve growth factors, nootropics, free oxygen radicals scavengers.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirák R. CURRENT TRENDS IN THE BIOLOGICAL TREATMENT OF ALZHEIMER DISEASE. Psychiatr. praxi. 2006;7(1):8-11.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aguglia E, Onor ML, et al. Comparison of rivastigmine, donepezil and galantamine in the real-world setting. Poster presented ad: 6th International Conference on Alzheimer´s and Parkinson´s; May 8-12, 2003: Seville, Spain.
    2. Alom J, Cras P, Jirák R, Korczyn AD, Lebluher F, et al. Donepezil for the treatment of Alzheimer´s disease: a multinational clinical experience study. In: 10th Congress of the International Psychogeriatric Association, Nice, 2001, abstrakt příspěvku zveřejněný ve sborníku.
    3. Areosa Sastre A, Sheriff F. Memantine for dementia (Cochrane review).In: The Cochrane Library, Issue 2 2003: Oxford. Go to original source...
    4. Arias E, Alés E, Gabilan NH, et al. Galantamine prevents apoptopsis induced by beta-amyloid and thapasigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004; 46: 103-114. Go to original source... Go to PubMed...
    5. Bae CH, Cho CY, Cho K, et al. A double-blind, placebo-controlled, multicentered study of cerebrolysin for Alzheimer´s disease. JAGS 2001; 48: 1566-1571. Go to original source... Go to PubMed...
    6. Birks J, Flicker L. Selegiline for Alzheimer´s disease. Cochrane Database Syst Rev 2000: 2. Go to original source...
    7. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer´s disease. In: The Cochrane Library, Issue 2, 2003: Oxford.
    8. Birks J, Grimley Evans J, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia (Cochrane Review). In: The Cochrane Library, Issue 2; 2003. Oxford. Go to original source... Go to PubMed...
    9. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer´s disease (Cochrane Review). In: The Cochrane Library, Issue 2; 2003. Oxford. Go to original source...
    10. Blesa R, Davidson M, Kurz A, et al. Galantamine provides sustained benefits in patients with advanced moderate Alzheimer´s disease for at least 12 months. Dement Geriatr Cogn Disord, 2003; 15: 79-87. Go to original source... Go to PubMed...
    11. Castellanos-Ortega MR, Cruz-Aguado R, Martinez-Marti L. Nerve growth gactor: possibilities and limitations of its clinical application. Rev Neurol, 1999; 29: 439-447. Go to original source...
    12. Cummings JL. Cholinesterase inhibitors: expanding indications. Lancet, 2000; 356: 2024-2025. Go to original source... Go to PubMed...
    13. Danisz W, Parsons CG, Möbius H-J, Stöffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer´s disease - a unified glutamatergic hypothesis of the mechanism of action. Neurotoxicity Research, 2000; 2: 85-97. Go to original source... Go to PubMed...
    14. Feldman H, (ed.) et al. Cholinesterase inhibitor therapy for Alzheimer´s disease and related dementias. Internat Psychogeriatrics, 2002; 14, Suppl. 1. Go to original source... Go to PubMed...
    15. Fioravanti M, Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 2; 2003. Oxford.
    16. Gauthier S. Acetylcholinesterase inhibitors in the treatment of Alzheimer´s disease. Exp Opin Invest Drugs, 1999; 8(10): 1511-1520. Go to original source... Go to PubMed...
    17. Giacobini E. Cholinesterases and cholinesterase inhibitors. Martin Dunitz, London, 2000: 270 s.
    18. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia (Cochrane Review). In: Cochrane Library, Issue 2; 2003. Oxford. Go to original source... Go to PubMed...
    19. Johannsen P, Hasselbach S, Jakab G, et al. Behavioral benefits with continued donepezil treatment in Alzheimer´s disease patients. Poster presented at the 8th Congress of the Eruropean Federation of Neurological Societies (EFNS), Sept. 4-7; 2004, Paris, France.
    20. Olin J, Schneider L. Galantamine for Alzheimer´s disease (Cochrane Review). In: The Cochrane Library, Issue 2; 2003. Oxford.
    21. Peskind ER, Potkin SG, Pomara N, et al. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer´s disease: A randomized controlled trial. Presented at the 8th Congress of European Federation of Neurological Societies, Sept. 4-7; 2004, Paris, France. Go to original source...
    22. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T, eds. Evidence-based Dementia practice. Oxford: Blackwell Science Ltd a Blackwell publishing company, 2003: 428-446.
    23. Rogers Sl, et al. A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer´s disease. Neurology, 1999; 50: 136-145. Go to original source... Go to PubMed...
    24. Rosler M, et al. Efficacy and safety of rivastigmine in patients with Alzheimer´s disease:international randomised controlled trial. Brit Med Journ, 1999; 318: 633-640. Go to original source... Go to PubMed...
    25. Sano M, et al. A controlled trial of selegiline, alpa-tocopherol or both as treatment for Alzheimer´s disease. The Alzheimer´s disease cooperative study. N Engl J Med, 1997; 336: 1216-1222. Go to original source... Go to PubMed...
    26. Scharf S, Mander A, et al. Double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer´s disease. Neurology 1999; 53: 197-201. Go to original source... Go to PubMed...
    27. Schenk D.: Opinion: Amyloid-beta immunotherapy for Alzheimer´s Disease: The End of Beginning. Nat Rev Neurosci, 2002, 3, 824-828. Go to original source... Go to PubMed...
    28. Scott HD, Laake K. Statins for the prevention of Alzheimer´s disease (Cochrane Review). In: The Cochrane Library, Issue 2; 2003, Oxford.
    29. Švestka J. Galantamin - dualistické kognitivum. Psychiatrie, 2001; 4: 2065-2074.
    30. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized, controlled trial. JAMA, Jan. 21, 2004; 291 (3): 317-324. Go to original source... Go to PubMed...
    31. Weinstock M. The pharmacotherapy of Alzheimer´s disease based on the cholinergic hypothesis:an update. Neurodegeneration 1995, Dec.; 4(4): 349-356. Go to original source... Go to PubMed...
    32. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer´s disease: multicentre randomised controlled trial. Galantamine international-1 study group. Brit Med Journ, 2000, Dec. 9; 32:1445-1449. Go to original source... Go to PubMed...
    33. Wilkinson D, Hammond G, Van Baelen B. Galantamine provides sustained benefits in patients with advanced moderate Alzheimer´s disease. Poster presented at the 8th European Federation of Neurological Societies, Paris, France, Sept. 4-7: 2004.
    34. Williams PS, Rands G, Orrel M, Spector A. Aspirin for vascular dementia (Cochrane review). The Cochrane Library, 2003: 2.
    35. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severly demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999 Feb; 14(2): 135-146. Go to original source...
    36. Yamada K, Witta A, Hasegava T, Fuji K, et al. Orally aktive NGF synthesis stimulators: Potential therapeutic agents in Alzheimer´s disease. Behav Brain Res, 1997; 83, 1-2: s. 117-122. Go to original source... Go to PubMed...
    37. Zoller B, Hock C, Kull HU. Rational therapy of Alzheimer´s dementia based on current clinical studies. Schweiz Rundsch Med Prax, 2001; May 10; 90(19): 827-834.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.